Smad7: Licensed to Kill β-Catenin

Research output: Contribution to journalShort surveypeer-review

15 Scopus citations


Elevated levels of inhibitory Smad7 are detected in several pathologic skin conditions; however the functional consequences of this expression have been unclear. A recent study shows that Smad7 overexpression in transgenic mouse epidermis at levels comparable to those seen in pathologic states is insufficient to block TGFβ or BMP signaling, but instead produces striking phenotypes due to degradation of β-catenin through a novel mechanism involving Smad7 and Smurf2.

Original languageEnglish
Pages (from-to)274-276
Number of pages3
JournalDevelopmental Cell
Issue number3
StatePublished - Sep 2006
Externally publishedYes


Dive into the research topics of 'Smad7: Licensed to Kill β-Catenin'. Together they form a unique fingerprint.

Cite this